Tags

Type your tag names separated by a space and hit enter

Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Manag Care Interface. 2003 Oct; 16(10):38-45.MC

Abstract

Drug tolerability strongly influences patients' persistence with treatment. In this study, patterns of medication persistence with cyclooxygenase 2 (COX-2)-specific inhibitors and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) were compared in a managed care setting. Pharmacy, enrollment, and medical claims data from 19 health plans were used to match subjects newly treated with celecoxib, rofecoxib, ibuprofen, naproxen, or diclofenac between July 1, 1999 and June 30, 2000. By using multiple regression analysis, users of COX-2-specific inhibitors were found to be 56.8% less likely to discontinue medication use and 60.3% less likely to switch treatment than were users of nonspecific NSAIDs (P < .001). Celecoxib users were 4.6% less likely to discontinue treatment than were rofecoxib users (P < .001). The greater persistence observed among users of COX-2 inhibitors might reflect improved treatment efficacy and patient satisfaction.

Authors+Show Affiliations

Research and Data Solutions at Ingenix, Inc., Eden Prairie, Minnesota, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14606259

Citation

Harley, Carolyn, and Samuel Wagner. "Persistence With COX-2 Inhibitors in Managed Care: an Analysis of Claims Data." Managed Care Interface, vol. 16, no. 10, 2003, pp. 38-45.
Harley C, Wagner S. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Manag Care Interface. 2003;16(10):38-45.
Harley, C., & Wagner, S. (2003). Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Managed Care Interface, 16(10), 38-45.
Harley C, Wagner S. Persistence With COX-2 Inhibitors in Managed Care: an Analysis of Claims Data. Manag Care Interface. 2003;16(10):38-45. PubMed PMID: 14606259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistence with COX-2 inhibitors in managed care: an analysis of claims data. AU - Harley,Carolyn, AU - Wagner,Samuel, PY - 2003/11/11/pubmed PY - 2004/1/9/medline PY - 2003/11/11/entrez SP - 38 EP - 45 JF - Managed care interface JO - Manag Care Interface VL - 16 IS - 10 N2 - Drug tolerability strongly influences patients' persistence with treatment. In this study, patterns of medication persistence with cyclooxygenase 2 (COX-2)-specific inhibitors and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) were compared in a managed care setting. Pharmacy, enrollment, and medical claims data from 19 health plans were used to match subjects newly treated with celecoxib, rofecoxib, ibuprofen, naproxen, or diclofenac between July 1, 1999 and June 30, 2000. By using multiple regression analysis, users of COX-2-specific inhibitors were found to be 56.8% less likely to discontinue medication use and 60.3% less likely to switch treatment than were users of nonspecific NSAIDs (P < .001). Celecoxib users were 4.6% less likely to discontinue treatment than were rofecoxib users (P < .001). The greater persistence observed among users of COX-2 inhibitors might reflect improved treatment efficacy and patient satisfaction. SN - 1096-5645 UR - https://www.unboundmedicine.com/medline/citation/14606259/Persistence_with_COX_2_inhibitors_in_managed_care:_an_analysis_of_claims_data_ L2 - https://medlineplus.gov/managedcare.html DB - PRIME DP - Unbound Medicine ER -